Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and immunogenicity of a new formulation of a pentavalent DTwP-HepB-Hib vaccine in healthy Indian infants-A randomized study.
Aloysia D'Cor N, Siddaiah P, Mohapatra S, Dhaded SM, I V P, Kar S, V N T, Muley P, Chhatwal J, Patnaik BN, Vidor E, Moureau A, Patel DM, Midde VJ, Jagga SR, Peesapati S, Noriega F. Aloysia D'Cor N, et al. Among authors: patel dm. PLoS One. 2023 Aug 15;18(8):e0284898. doi: 10.1371/journal.pone.0284898. eCollection 2023. PLoS One. 2023. PMID: 37582114 Free PMC article. Clinical Trial.
Persistence of Hepatitis B Immune Memory Until 6 Years of Age Following Hexavalent DTaP-IPV-HB-PRP~T Vaccination in a 3-, 5- and 11- to 12-month Schedule and Response to a Subsequent Hepatitis B Challenge Vaccination.
Virta M, Soininen A, Patel DM, Petit C, Tabar C, Lyabis O. Virta M, et al. Among authors: patel dm. Pediatr Infect Dis J. 2021 Jan;40(1):e28-e30. doi: 10.1097/INF.0000000000002954. Pediatr Infect Dis J. 2021. PMID: 33284254 Clinical Trial.
Safety and immunogenicity of Clostridium difficile toxoid vaccine in Japanese adults.
Matsuoka O, Patel DM, Sasaki S, Oka H, Sasaki T, Pietrobon PJ, Laot T, Bouckenooghe A, Menezes J, de Bruyn G. Matsuoka O, et al. Among authors: patel dm. Hum Vaccin Immunother. 2018 Feb 1;14(2):322-328. doi: 10.1080/21645515.2017.1395538. Epub 2017 Dec 6. Hum Vaccin Immunother. 2018. PMID: 29116880 Free PMC article. Clinical Trial.
Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial.
de Bruyn G, Gordon DL, Steiner T, Tambyah P, Cosgrove C, Martens M, Bassily E, Chan ES, Patel D, Chen J, Torre-Cisneros J, Fernando De Magalhães Francesconi C, Gesser R, Jeanfreau R, Launay O, Laot T, Morfin-Otero R, Oviedo-Orta E, Park YS, Piazza FM, Rehm C, Rivas E, Self S, Gurunathan S. de Bruyn G, et al. Lancet Infect Dis. 2021 Feb;21(2):252-262. doi: 10.1016/S1473-3099(20)30331-5. Epub 2020 Sep 15. Lancet Infect Dis. 2021. PMID: 32946836 Clinical Trial.
Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized Phase 2 clinical trial.
de Bruyn G, Saleh J, Workman D, Pollak R, Elinoff V, Fraser NJ, Lefebvre G, Martens M, Mills RE, Nathan R, Trevino M, van Cleeff M, Foglia G, Ozol-Godfrey A, Patel DM, Pietrobon PJ, Gesser R; H-030-012 Clinical Investigator Study Team. de Bruyn G, et al. Among authors: patel dm. Vaccine. 2016 Apr 27;34(19):2170-8. doi: 10.1016/j.vaccine.2016.03.028. Epub 2016 Mar 21. Vaccine. 2016. PMID: 27013431 Free article. Clinical Trial.
Multidimensional analyses reveal modulation of adaptive and innate immune subsets by tuberculosis vaccines.
Rozot V, Nemes E, Geldenhuys H, Musvosvi M, Toefy A, Rantangee F, Makhethe L, Erasmus M, Bilek N, Mabwe S, Finak G, Fulp W, Ginsberg AM, Hokey DA, Shey M, Gurunathan S, DiazGranados C, Bekker LG, Hatherill M, Scriba TJ; C-040-404 Study Team. Rozot V, et al. Commun Biol. 2020 Oct 9;3(1):563. doi: 10.1038/s42003-020-01288-3. Commun Biol. 2020. PMID: 33037320 Free PMC article. Clinical Trial.
199 results